Edwards Lifesciences Corporation
EWHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeEdwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. With a market capitalization of $51.82B, it sits in large-cap territory. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands.
Market Cap
$51.82B
Beta
0.85
P/E (TTM)
53.51
P/E (Fwd)
26.62
EPS (TTM)
$1.68
EPS (Fwd)
$3.38
ROE
9.2%
ROA
8.4%
Cash
$4.25B
Total Debt
$704.4M
Free CF
$1.23B
52W Change
12.1%
Annual Financials
Cash vs Debt
Where EW stands vs its 150-day and 200-day moving averages
As of the August 26, 2026 close, EW finished 7.35% above its 150-day moving average ($84.65) and 7.26% above its 200-day moving average ($84.72). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is EW overbought or oversold?
At the August 26, 2026 close, EW's RSI(14) was 57.5, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $4.25B in cash comfortably exceeding the $704.4M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow comes in at $1.23B, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 9.2%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 8.4% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $4.46B (2022) to $6.07B (2025), reflecting a 36% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing EW.